Tags

Type your tag names separated by a space and hit enter

Immunomodulation and Regenerative Capacity of MSCs for Long-COVID.
Int J Mol Sci. 2021 Nov 17; 22(22)IJ

Abstract

The rapid mutation of the SARS-CoV-2 virus is now a major concern with no effective drugs and treatments. The severity of the disease is linked to the induction of a cytokine storm that promotes extensive inflammation in the lung, leading to many acute lung injuries, pulmonary edema, and eventually death. Mesenchymal stem cells (MSCs) might prove to be a treatment option as they have immunomodulation and regenerative properties. Clinical trials utilizing MSCs in treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) have provided a basis in treating post-COVID-19 patients. In this review, we discussed the effects of MSCs as an immunomodulator to reduce the severity and death in patients with COVID-19, including the usage of MSCs as an alternative regenerative therapy in post-COVID-19 patients. This review also includes the current clinical trials in utilizing MSCs and their potential future utilization for long-COVID treatments.

Authors+Show Affiliations

Centre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.Centre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor 11800, Malaysia.Department of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, Kuala Lumpur 50603, Malaysia. Centre for Innovation in Medical Engineering (CIME), Department of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, Kuala Lumpur 50603, Malaysia.Centre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34830303

Citation

Loke, Xin Ya, et al. "Immunomodulation and Regenerative Capacity of MSCs for Long-COVID." International Journal of Molecular Sciences, vol. 22, no. 22, 2021.
Loke XY, Imran SAM, Tye GJ, et al. Immunomodulation and Regenerative Capacity of MSCs for Long-COVID. Int J Mol Sci. 2021;22(22).
Loke, X. Y., Imran, S. A. M., Tye, G. J., Wan Kamarul Zaman, W. S., & Nordin, F. (2021). Immunomodulation and Regenerative Capacity of MSCs for Long-COVID. International Journal of Molecular Sciences, 22(22). https://doi.org/10.3390/ijms222212421
Loke XY, et al. Immunomodulation and Regenerative Capacity of MSCs for Long-COVID. Int J Mol Sci. 2021 Nov 17;22(22) PubMed PMID: 34830303.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunomodulation and Regenerative Capacity of MSCs for Long-COVID. AU - Loke,Xin Ya, AU - Imran,Siti A M, AU - Tye,Gee Jun, AU - Wan Kamarul Zaman,Wan Safwani, AU - Nordin,Fazlina, Y1 - 2021/11/17/ PY - 2021/10/05/received PY - 2021/11/08/revised PY - 2021/11/10/accepted PY - 2021/11/27/entrez PY - 2021/11/28/pubmed PY - 2021/11/28/medline KW - MSCs KW - immunomodulation KW - long-COVID KW - regeneration JF - International journal of molecular sciences JO - Int J Mol Sci VL - 22 IS - 22 N2 - The rapid mutation of the SARS-CoV-2 virus is now a major concern with no effective drugs and treatments. The severity of the disease is linked to the induction of a cytokine storm that promotes extensive inflammation in the lung, leading to many acute lung injuries, pulmonary edema, and eventually death. Mesenchymal stem cells (MSCs) might prove to be a treatment option as they have immunomodulation and regenerative properties. Clinical trials utilizing MSCs in treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) have provided a basis in treating post-COVID-19 patients. In this review, we discussed the effects of MSCs as an immunomodulator to reduce the severity and death in patients with COVID-19, including the usage of MSCs as an alternative regenerative therapy in post-COVID-19 patients. This review also includes the current clinical trials in utilizing MSCs and their potential future utilization for long-COVID treatments. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/34830303/Immunomodulation_and_Regenerative_Capacity_of_MSCs_for_Long_COVID_ L2 - https://www.mdpi.com/resolver?pii=ijms222212421 DB - PRIME DP - Unbound Medicine ER -